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Abstract  
Elevated levels of vascular endothelial growth factor (VEGF)A are thought to cause glomerular 
endothelial cell (GEnC) dysfunction and albuminuria in diabetic nephropathy. We hypothesized 
that VEGFC could counteract these effects of VEGFA to protect the glomerular filtration barrier 
and reduce albuminuria. Isolated glomeruli were stimulated ex vivo with VEGFC, which reduced 
VEGFA- and type II diabetes-induced glomerular albumin permeability (Ps’alb). VEGFC had no 
detrimental effect on glomerular function in vivo when over-expression was induced locally in 
podocytes (podVEGFC) in otherwise healthy mice. Further, these mice had reduced glomerular 
VEGFA mRNA expression, yet increased glomerular VEGF receptor heterodimerization 
indicating differential signalling by VEGFC. In a model of type I diabetes, induction of podocyte 
VEGFC over-expression reduced the development of hypertrophy, albuminuria, loss of GEnC 
fenestrations and protected against altered VEGF receptor expression. In addition, VEGFC 
protected against raised Ps’alb by endothelial glycocalyx disruption in glomeruli. In summary 
VEGFC; reduced the development of diabetic nephropathy; prevented VEGF receptor alterations 
in the diabetic glomerulus; promoted both glomerular protection and endothelial barrier function. 
These important findings highlight a novel pathway for future investigation in the treatment of 
diabetic nephropathy. 
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Introduction 
Systemic endothelial dysfunction is an initiating step in the development of vascular damage 
in diabetes (1; 2) and is associated with microalbuminuria (urinary albumin secretion, 30-
300mg/day) (3). It is widely accepted that microalbuminuria indicates disruption of the 
glomerulus and is the earliest clinically detectable indicator of incipient diabetic nephropathy 
(DN) (4). Glomerular endothelial cells (GEnC) restrict the passage of protein across the highly 
specialized glomerular capillary wall via the luminal facing endothelial glycocalyx (eGLX), 
which consists of proteoglycans, glycosaminoglycans, glycoproteins and trapped soluble plasma 
proteins. GEnC have trans-cellular fenestrations that form in attenuated areas of GEnC 
cytoplasm which constitute 20-50% of the entire endothelial cell surface (5). Fenestrae are 
necessary for the high permeability of the glomerulus to water and small solutes (5). However, 
fenestrae are covered by eGLX (6) which is known to regulate vascular permeability (7-10), by 
limiting the passage of charged macromolecules (11).  
 Vascular endothelial growth factor (VEGF)-A is highly expressed by podocytes in the 
glomerulus (12) and provides essential maintenance signals for GEnC including those for 
survival and regeneration (13), maintaining fenestrations (14) and regulating solute flux and 
protein passage (15; 16). Systemic and glomerular vessels become more “leaky” in pathological 
conditions where VEGFA bioavailability is increased, such as cancer, retinal disease (17) and 
early DN (18; 19). Blockade of VEGFA in these experimental models reduces vascular 
permeability (20; 21), including proteinuria in DN (6; 22). However, clinical anti-VEGFA 
therapies (23-25) can cause proteinuria and hypertension (26) confirming that some VEGFA is 
necessary for endothelial maintenance. Therefore, strategies which block adverse effects of 
excessive VEGFA, but do not remove it completely would be attractive for DN.  
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VEGFC, a lymphangiogenic growth factor, is also expressed by podocytes (27), despite an 
absence of lymphatic vessels in glomeruli. VEGFC typically signals though VEGFR3, 
predominantly expressed in lymphatic endothelial cells (LEC), but can induce similar 
“maintenance” signals as VEGFA in vascular endothelial cells (28) acting though VEGFR3, 
VEGFR2 or heterodimers of both (29). VEGFC can also induce fenestration formations in the 
vascular endothelium, but to a lesser extent than VEGFA (30).  
VEGFA predominantly signals through phosphorylation of VEGFR2  (31). We have shown 
that VEGFA induces transient VEGFR2 phosphorylation after 2min in human conditionally 
immortalized (ci)GEnC (32). VEGFC also induced VEGFR2 phosphorylation in these cells, 
maximally at 30min, but did not induce VEGFR3 phosphorylation. VEGFC induced a 
correspondingly slower rise in intracellular calcium than VEGFA and did not result in VE-
Cadherin phosphorylation. We hypothesise that such differences in intracellular events underlie 
our observation that VEGFA increases permeability of ciGEnC monolayers to protein while 
VEGFC reduces protein permeability and blocks the effect of VEGFA (32). Additionally, 
VEGFC enhances the eGLX layer in vitro, in contrast to VEGFA which increases eGLX 
shedding (32; 33).  
Together, these data suggest that VEGFC may be able to ameliorate albuminuria by reducing 
the permeability of GEnC to protein, whilst retaining high water permeability. Thus, the effect of 
VEGFC on raised glomerular albumin permeability was assessed under various conditions and 
VEGF-C receptor signalling was explored. Finally, the mechanism of VEGFC action on GEnC 
barrier properties were investigated with a specific focus on the eGLX.  
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Research design and methods 
Glomerular endothelial cell culture: Human conditionally immortalised glomerular endothelial 
cells (ciGEnC) were maintained and propagated in culture as described (34). ciGEnC, stably 
transfected with GFP-tagged VEGFR2 (ciGEnC/GFP-VEGFR2) (a kind gift from Prof Harry 
Mellor, University of Bristol) were cultured similarly. 
Recombinant proteins: Human recombinant VEGFA and VEGFC (R&D Systems) were 
reconstituted as previously and used at final concentrations of 1nM (42 ng/ml) and 10nM (210 
ng/ml) respectively as previously (32).  
Antibodies: All primary and secondary antibodies that were used and their dilutions are described 
in table 1 (supplementary material). 
Immunofluorescence: Immunofluorescence was carried out on fresh frozen mouse kidney 
sections as previously (35) and on GEnC as previously  (33). The integrated density of 
glomerular VEGFC was semi-quantified using Image J (15 glomeruli per animal) and expressed 
as fold change to littermate control mice (LMC). For cellular VEGFR3 quantification, images 
were acquired using the InCell Analyzer 2200 system (GE Healthcare) as previously (36). In 
brief, analysis was performed using InCell Analyzer 1000 Workstation Multi-target analysis 
algorithms using phalloidin to define the cell and DAPI to segment the nuclei. VEGFR3 is 
reported as mean fluorescence intensity per cell.   
Western blotting: ciGEnC, tissue, sieved glomeruli and flow-through  were lysed in RIPA buffer 
containing phosphatase and protease inhibitors. Samples were quantified (bicinchoninic acid 
assay, Pierce; Thermo Fisher Scientific) and Western blotted.  
RNA extraction and PCR: RNA was extracted from isolated mouse glomeruli using a RNeasy 
Mini kit (Qiagen) according to manufacturer’s instructions. Primer sequences were predesigned, 
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selected from http://pga.mgh.harvard.edu/primerbank/ and optimized as previously described 
(33). Human GAPDH primers were used as previously (33), with other primer pairs described in 
table 2 (supplementary material). QPCR was carried out as previously described (33). 2-^^CT 
(relative fold change) was calculated from the CT values generated. 
VEGFR3 Immunoprecipitations (IP): Mouse lungs and glomeruli were freshly harvested in ice 
cold PBS containing 100µm Na3VO4 and protease inhibitor cocktails (1:100, Sigma). These 
tissues were then treated with VEGFA and VEGFC or vehicle at 37°C for 2, 15 or 30min. PBS 
was removed and samples resuspended in 100µl NP40 lysis buffer, then pre-cleared. Equal 
quantities of protein, made to 500µl, were incubated at 4°C for 18h with 1.5µg/100µg protein of 
anti-mouse VEGFR3 (ALF4) (eBioscience). Subsequently, 60µl of equilibrated A/G PLUS-
agarose beads (Santa Cruz) were added to each sample and incubated at 4°C for 6h. Beads were 
centrifuged and supernatant samples were taken for immunoblotting. Thirty microlitres of IP 
samples and equal protein concentrations of supernatant and total protein were loaded onto an 
SDS PAGE gel and Western blotted.  
Podocin rtTA, Tet-O-VEGFC (podVEGFC) mice: Podocin rtTA (podrtTA) mice expressing the 
transgene exclusively in podocytes (37) were a kind gift from Prof Jeffrey Kopp, NIH 
(FVB/mixed). Tet-O-VEGFC mice (FVB/N), containing full length mouse VEGFC were used as 
previously described (38). Heterozygous podrtTA mice were crossed with heterozygous Tet-O-
VEGFC mice to obtain mice heterozygous for both transgenes (podVEGFC) and LMC mice. 
Animals were kept according to the “Guidelines on the Use of Animals in Research,” and the 
number of animals used was kept to a minimum. Mice were housed in a pathogen-free 
environment at 21°C, with a 12-h light-dark cycle, and all received a standard laboratory animal 
diet (Beekey Feeds) and water ad libitum.  
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Animal genotyping: Ear notches were digested in 20µl digestion buffer (1X PCR buffer (supplied 
with Hotmaster taq) 0.0045% NP40, 0.0045% Tween 20, 1mg/ml proteinase K). Samples were 
digested for 2hs at 60°C, then 15min at 95°C. PCR for podrtTA was carried out as originally 
described (37). For Tet-O-VEGFC, primers are described in table 2 (supplementary material). 
The PCR reaction (total volume 13µl) contained 6.5µl Mastermix buffer (Amplitaq Gold 360, 
Applied Biosystems) and 0.5µM primers. PCR cycle conditions were as follows; 1 cycle at 95°C 
for 10min, 42 cycles of 1 cycle at 95°C for 30sec, 68°C 30sec, 72°C for 60sec and 72°C for 
7min.  
Induction of podocyte VEGFC overexpression in transgenic mice. Expression of podocyte 
VEGFC was induced by doxycycline (2 mg/ml) in the drinking water with sucrose (5% wt/vol) 
as previously shown (37). Doxycycline was replaced every 3-4 days and protected from light at 
all times. If mice did not drink the doxycycline water they received chow supplemented with 
625mg/kg doxycycline (Harlan Laboratories UK), observed to increase VEGFC mRNA 
expression to a similar extent (0.9-fold change VEGFC mRNA expression compared to 
doxycycline supplemented water, data not shown). Some animals were given sucrose alone. 
Urine samples were collected weekly in metabolic cages with environmental enrichment up to 6h 
at a time.  
Type II diabetic mice: 12-14 wk old male C57BLKsJ-db/db (db/db) mice (Harlan Laboratories, 
UK) were used as a model of severe spontaneous Type II diabetes. Age matched, male 
C57BLKsJ-db/+ (db/+) lean mice were used for comparison. mRNA was extracted from 
enriched glomeruli from 7wk old db/db and db/+ mice. Urinary albumin creatinine ratio (uACR) 
and glucose levels were measured as below.  
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Induction of Type I Diabetes: Diabetes was induced in 8-10wk podVEGFC and LMC mice using 
a low-dose (50mg/Kg/day over 5 consecutive days) streptozotocin (STZ) induction protocol as 
previously (39) (as advised by DiaComp https://www.diacomp.org/). Mice were checked for 
adverse effects following dosing; animals that demonstrated dehydration (including weight loss, 
slack skin or bloating due to constipation-revealed by post-mortem in the first few diabetic mice) 
were supplemented with ‘mash’ and DietGel with subcutaneous 0.9% saline injections as 
necessary. Blood glucose levels were monitored weekly from a tail-tip blood droplet using an 
Accu-check (Aviva) blood glucose meter. Animals with blood glucose above 15mmol/L 2wk 
after injections were included in the study. Body weight was monitored regularly. Mice received 
doxycycline from 0wk (prevention) or 4wk (rescue) after STZ administration. Urine was 
collected as previously, although as animals became more polyuric the collection time was 
reduced to minimise water weight loss and stress. 
Glomerular albumin permeability (Ps’alb) assay: This assay was developed and extensively 
characterized previously(40). In brief, mice were anaesthetised and the kidneys perfused with 4% 
BSA (RingerBSA), followed by 36.5µg/ml Octadecyl rhodamine B chloride (R18) 
(ThermoFisher Scientific) to label cell membranes, then 30µg/ml AlexaFluor (AF)488-BSA 
(labelled albumin) (Life technologies). Glomeruli were isolated from kidney cortex by graded 
sieving. For glomeruli treated ex vivo, glomeruli loaded with AF488-BSA were held on ice until 
treated with VEGFA, VEGFC, both VEGFA and VEGFC, or an equal volume of Ringer-BSA 
(vehicle) for 1h at 37°C. Individual glomeruli were transferred to a Nikon TIE inverted confocal 
microscope and trapped before the perfusate was switched from 30µg/ml AF488-BSA to 
30µg/ml unlabelled BSA. The rate of decrease in fluorescent intensity within capillary loops was 
quantified and from this apparent albumin solute permeability (Ps’alb) was calculated(40) : 
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  PSalb = -kR/2                                                                                                                               
In vivo eGLX disruption: We have shown previously that chondroitinase and hyaluronidase 
given acutely, i.v. 30min before sacrifice raises Ps’alb significantly and causes a reduction in 
eGLX coverage(40) . In the same cohort of animals, glomeruli were isolated and incubated in 
VEGFC as described above and Ps’alb measured and compared. Further, chondroitinase and 
hyaluronidase were administered chronically, via an osmotic minipump (Charles River UK Ltd, 
Kent, UK, 0.25µl/h), cannulated to the jugular, for a total of 2 wk (0.087 mU/g chondroitinase 
and 15 mU/g hyaluronidase, or vehicle over a 24h period, equivalent to 0.004mU/h 
chondroitinase and 0.625U/h hyaluronidase). In the final week a VEGFC intervention was given 
to half of the enzyme treated mice i.p daily (100 ng/g body wt as previously(40) ). Glomeruli 
were isolated and Ps’alb was measured.  
Electron microscopy: Mice were whole body perfusion fixed with Glutaraldehyde containing 
Alcian blue. Electron micrographs were taken using a Technai 12 electron microscope and 
images analysed as previously (39). 
Urinary albumin creatinine ratio (uACR): Mouse uACR were quantified as previously described 
(39) and expressed as log fold change to baseline. 
Glomerular isolation: To achieve a >97% pure population of isolated glomeruli, Dynabeads 
were cardiac perfused as originally described by Takemoto et al (43) and placed in RNA later 
(Invitrogen). Alternatively, to obtain a glomerular enriched population, kidneys were mashed and 
glomeruli isolated through graded sieving and collected from 75µm2 pore sieves for protein or 
mRNA extraction. To demonstrate glomerular enrichment, kidney cortex, flow-through and 
sieved glomeruli were collected and lysates were extracted, quantified and Western blotted as 
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above. Blots were probed with anti-nephrin, anti-CD13 and anti actin antibodies (table 1, 
supplementary materials). 
Proximity Ligation Assay (PLA): Fresh-frozen mouse kidney sections were fixed in 4% PFA and 
permeabilised using 0.1% Triton-X. Samples were then treated with the Proximity Ligation 
Assay Kit (Olink Bioscience) according to the manufacturer’s instructions. In brief, primary 
antibodies or matched concentration IgG controls in various combinations were incubated 
together overnight (see table 1, supplementary materials for details), followed by incubation with 
goat MINUS and rabbit PLUS probes. Nuclei were counterstained using DAPI (1:1000 diluted in 
PLA kit 0.01x wash buffer B). Images were quantified, by a blinded analyser using ImageJ, by 
counting the number of punctate dots through z-stack of images and normalising to the number 
of nuclei within the field of view. Three representative z-stacks from each sample were analysed. 
Periodic acid-Schiff’s (PAS) staining of mouse kidney sections: Paraffin embedded mouse kidney 
sections were stained using a PAS kit (Sigma-Aldrich) according to the manufactures’ 
instructions. Six glomerular images were analysed per mouse and quantified as previously (40).  
Picrosirius Red Staining: Mouse tissue sections were hydrated followed by counterstaining in a 
0.1% (w/v) Direct Red 80 powder (Sigma) in a 1.3% saturated aqueous solution of picric acid 
(VWR Chemicals) for 90min at room temperature, then dehydrated and mounted. Images were 
taken using bright field (to indicate collagen I and III) and polarizing lens’ (to distinguish 
between type I (yellow-orange) and type III (green-white) newly laid collagen fibers). 
Statistical analysis: All statistical analysis was carried out on a minimum of 3 separate 
experiments. In Ps’alb experiments, data are presented as means of measurements from 
glomeruli to show the spread of data points, but for statistical purposes the means from 
individual animals were used. In experiments with multiple treatments, a one-way ANOVA was 
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used with Bonferroni’s multiple comparison post hoc test, unless indicated otherwise. A p value 
of less than 0.05 was considered statistically significant. Error bars indicate the standard 
deviation. 
13 
 
Results 
VEGFC prevents the increase in glomerular albumin permeability caused by VEGFA and 
type II diabetes and is cytoprotective for GEnC.  
To test whether VEGFC could protect against the effects of raised VEGFA, an ex vivo 
isolated glomerular Ps’alb assay was utilized that we recently published(40) . VEGFA 
significantly increased Ps’alb in isolated glomeruli as anticipated in FVB/mixed background (fig 
1A) and db/- (lean) mice (fig 1B). Importantly, this effect was prevented by VEGFC, yet 
VEGFC alone did not change Ps’alb. To understand whether VEGFC could rescue albumin 
permeability induced by diabetes, glomeruli were isolated from db/db (type II diabetic) mice and 
stimulated with VEGFC ex vivo as above. Ps’alb in diabetic glomeruli was significantly raised, 
as anticipated, whereas it was significantly rescued by VEGFC (fig 1C). Db/db mice were 12-14 
wk old, had significant proteinuria (fig 1D) and were hyperglycemic (fig 1E). We confirmed that 
there was a significant increase in VEGFA mRNA expression in enriched glomeruli from db/db 
mice (fig 1F). We also confirmed that VEGFC was cytoprotective for GEnC, an important 
protective effect of VEGFA. Using a trypan blue viability assay we determined that GEnC were 
protected from death (serum free, volume reduced media) by VEGFC over 24h in a similar 
manner to VEGFA (supp fig 1A). This was associated with increased Akt phosphorylation over 
time by VEGFC and VEGFA (supp fig 1B), suggesting that VEGFC promotes survival in GEnC 
in a similar manner to VEGFA in vitro.  
Characterization of podVEGFC mice 
To determine whether VEGFC could be protective in vivo, we generated a podVEGFC 
mouse (fig 2A). Firstly, glomeruli were Dynabead isolated from podVEGFC and LMC mice 
after receiving doxycycline for 3wk. Quantitative PCR revealed a significant increase in 
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normalized VEGFC glomerular mRNA expression in podVEGFC mice (fig 2B) This was 
supported by immunofluorescence showing co-localisation of VEGFC with nephrin (C) in 
podVEGFC mice. Semi-quantification demonstrated significantly increased glomerular protein 
expression in podVEGFC mice (fig 2D). Levels of VEGFC mRNA were similar in glomeruli 
isolated by Dynabead and sieving protocols (data not shown), therefore sieving was used to 
isolate glomeruli hereafter. 
VEGFC has no detrimental effect on glomerular function 
Glomerular parameters in podVEGFC mice were compared to LMC. There was no renal 
hypertrophy (fig 2E), mesangial matrix expansion (fig 2Fi&G) or ultrastructural changes in 
GMB thickness, podocyte foot process width, slit diaphragm length (fig 2Fii&Hi), fenestration 
density (fig 2I) or in uACR (fig 2J) up to 8wk after induction of VEGFC expression. Together, 
these results demonstrate that VEGFC does not significantly affect glomerular structure or 
function over prolonged periods of exposure, in contrast to VEGFA (44).  
Glomerular VEGFC expression affects VEGF signalling  
Glomerular sieving successfully enriched the glomeruli population (supp fig 2). In 
podVEGFC mice there was a trend towards a reduction in VEGFR2 in the glomerular enriched 
fraction (fig 3A), but no significant reduction in VEGFR3 mRNA expression (fig 3B). VEGFA 
mRNA expression was significantly reduced (fig 3C). In non-permeabilised cells both VEGFA 
and VEGFC reduced cell surface VEGFR3 expression at 2min (fig 3D), whilst total VEGFR2 
and VEGFR3 expression was unaffected by VEGFA or VEGFC at 2min (supp fig 3). VEGFR3 
and VEGFR2 heterodimerisation by VEGFC, as reported previously elsewhere (29; 45), was 
investigated ex vivo in isolated glomeruli using immunoprecipitation. VEGFR2 was not pulled 
down by VEGFR3 in response to VEGFC (fig 3E). However, heterodimers were formed in 
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response to VEGFC in mouse lungs as anticipated (fig 3F). Nilsson et al demonstrated that a 
proximity ligation assay (PLA) was more sensitive to detect VEGFR2/VEGFR3 
heterodimerisation than immunoprecipitation (29). Thus, a PLA was used on fresh frozen 
sections from podVEGFC and LMC mice (fig 3G). Optimisation, by replacing primary 
antibodies with matched concentration IgG, demonstrated specificity of punctate staining (supp 
fig 4). There was a significant increase in punctate fluorescent events, indicating 
heterodimerization, throughout the Z stacks of each glomerular cell in podVEGFC mice 
compared to LMC mice (fig 3H).  
Early glomerular VEGFC expression reduces the development of DN 
Endothelial dysfunction develops early in diabetes and manifests as microalbuminuria in 
the kidney. We have shown that VEGFC ameliorates raised Ps’alb associated with type II 
diabetes in isolated glomeruli. To understand whether VEGFC could prevent albuminuria in DN, 
doxycycline was administered before STZ injections (fig 4A). Diabetic mice (D-) were 
hyperglycemic (fig 4B), had reduced body weight (fig 4C) and increased urine output (fig 4D), 
as anticipated. D-podVEGFC mice did not have significant renal hypertrophy (fig 4E) and had a 
significantly reduced fold change in uACR compared to D-LMC mice (fig 4F, please refer to 
supp fig 5A for absolute values), which was high but variable due to the mixed background of 
the mice. Diabetes did not significantly increase GBM thickness or podocyte foot process width 
(fig 4G&H). However, podocyte slit diaphragm narrowing was evident in D-LMC mice (fig 
4G&H). D-LMC mice had significantly lower endothelial fenestration density than LMC, 
whereas D-podVEGFC did not (fig 4G&I).  
Glomerular VEGFC intervention reduces the development of DN 
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To understand whether VEGFC could rescue DN after diabetes was established, 
doxycycline was administered 4wk post STZ injections (fig 5A). Diabetic mice were 
hyperglycemic (fig 5B) and polyuric (fig 5C) as anticipated. There was no significant difference 
in weight gain between groups, however, these diabetic mice were susceptible to intestinal 
bloating which was likely to mask body weight reductions (this protocol was carried out 
chronologically before the one described above, and this issue was mitigated as described in the 
methods) (fig 5D). Of note, this cohort of mice also had a lower starting weight than the 
intervention cohort in fig 4, and sham mice did not gain weight as rapidly which may confound 
the results. Elevated plasma uric acid is associated with diabetes and can be caused by 
hyperglycemia (46). Plasma uric acid was significantly raised in both diabetic groups as 
anticipated (fig 5E). Importantly, renal hypertrophy (fig 5F) was significantly increased in D-
LMC mice, but significantly reduced in D-podVEGFC mice.  Fold change in uACR (fig 5G, 
please refer to supp fig 5B for absolute values) was significantly increased in D-LMC mice but 
not in D-podVEGFC mice. Mesangial matrix expansion was significantly reduced in D-
podVEGFC mice (fig 5H&K), supported by decreased collagen deposition (Fig 5I, J). There was 
no significant effect of diabetes on GBM thickness, consistent with an early phenotype of DN 
(fig 6A-B). D-LMC had significantly increased podocyte foot process width and both D-LMC 
and D-podVEGFC had significantly reduced slit diaphragm width (fig 6B). D-LMC also had 
significantly reduced fenestration density (fig 6C) demonstrating the early development of 
diabetic nephropathy. Together, these data from both diabetic cohorts suggest that early VEGFC 
intervention may reduce the development of early DN.  
Glomerular VEGFC prevents the diabetes associated changes in VEGFR expression 
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Induction of VEGFC expression was confirmed in glomerular fractions from D-
podVEGFC mice (fig 7A) in a similar manner to podVEGFC mice. There was no significant 
change in endogenous glomerular fractions of VEGFC expression between D-LMC and sham-
LMC mice (fig 7B). VEGFA mRNA from glomerular fractions was increased by diabetes (fig 
7C), as previously shown (47), with a trend towards increase in D-podVEGFC mice (fig 7C). 
VEGFR2 and VEGFR3 mRNA from glomerular fractions were significantly increased in D-
LMC mice, but not D-podVEGFC  (fig 7D-E). This was supported by VEGFR2 protein analysis 
whereby VEGFR2 expression was significantly reduced in D-podVEGFC mice (fig 7F, G). Of 
note, VEGFR2 protein was undetected in sieved flow-through fractions (supp fig E), suggesting 
that VEGFR2 protein changes were glomerular specific. VEGFR3 protein analysis was not 
significant (fig 7F, H). In summary, VEGFC prevented VEGFR changes associated with DN. 
VEGFC protects against raised Ps’alb caused by systemic eGLX dysfunction 
We have previously shown that VEGFC increases the synthesis of sulphated and non-
sulphated glycosaminoglycans (GAG) in GEnC-GLX in vitro (33). Since macromolecular barrier 
properties in GEnC are governed by eGLX (48) we investigated the potential for VEGFC to 
reduce Ps’alb in an eGLX dependent manner. Previously, we demonstrated that a bolus of 
hyaluronidase and chondroitinase 30min before sacrifice significantly reduced eGLX coverage 
and significantly increased Ps’alb(40) . In the same cohort of mice, isolated glomeruli were 
stimulated with VEGFC for 1hr. In these glomeruli, VEGFC rescued the effect of eGLX 
disruption on Ps’alb (fig 8A). We followed this experiment with chronic, systemic exposure to 
these enzymes (2wk) with VEGFC i.p. injections given in the last week. Enzymes significantly 
increased Ps’alb in isolated glomeruli. However, this was significantly prevented in glomeruli 
from mice with given the VEGFC intervention (fig 8B). Electron micrographs from mice in 
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parallel experiments demonstrated that GAG enzymes significantly reduced GEnC eGLX depth, 
but not in the presence of VEGFC (fig 8C-D). Interestingly podocyte glycocalyx was relatively 
unaffected (fig 8D). To demonstrate no off-target effects of the GAG enzymes, glomerular 
ultrastructural parameters were measured. There were no significant effects of enzymes on GBM 
width (although the combination of enzymes plus VEGFC significantly reduced GBM width), 
slit diaphragm width, podocyte foot process density (fig 8E, although there was a significant 
overall effect) or endothelial fenestration density (fig 8F). In summary VEGFC can protect from 
increased Ps’alb under eGLX dysfunction, suggesting the possibility that VEGFC protection 
from albuminuria is eGLX dependent.  
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Discussion 
In this study, we demonstrate for the first time that VEGFC can protect against VEGFA-
induced glomerular albumin permeability and can restore glomerular albumin permeability in 
type II diabetes. Also, it can ameliorate early DN in type I diabetes; reducing fibrosis, kidney 
hypertrophy, loss in glomerular endothelial fenestration density, and reducing albuminuria. 
There was an 89% reduction in albuminuria when VEGFC was used preventatively and a 67% 
reduction when VEGFC was used to rescue changes. These were comparable to previously 
published results demonstrating that glomerular over-expression of angiopoietin-1 in diabetic 
mice caused a 70% reduction in albuminuria (49) and glomerular over-expression of VEGFA165b 
in diabetic mice caused an 80% reduction in albuminuria (50). That VEGFC reversed the 
increased glomerular albumin permeability in type II diabetic glomeruli confirms the effect of 
VEGFC across mouse strains and diabetes type. This demonstrates that VEGFC can act as an 
anti-albuminuric agent in experimental DN. 
Diabetes-induced damage to glomerular ultrastructure included foot process flattening and 
reduced endothelial fenestration density (51-53). Reduced fenestration density is an established 
feature of DN in humans, which is positively correlated with uACR (52). It has been suggested 
that loss of GEnC fenestration density reflects both glomerular filtration rate and uACR better 
than changes in podocyte parameters (54). Of note we did not see any changes in GBM 
thickness. This is surprising, but may be a reflection that podocyte damage is not yet severe 
enough to impact maintenance of the GBM (55), or may simply be a reflection of mixed strain 
background. Notably the D-podVEGFC mice did not have significantly reduced fenestration 
density. It is well established that GEnC fenestration density is reduced in DN. Fenestrations are 
too large to restrict albumin passage, however loss of fenestration density, or organization, may 
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reflect a loss of filtration control. Also, renal hypertrophy was reduced in D-podVEGFC mice. 
Although our mice have early diabetic nephropathy they also have evidence of fibrosis, 
demonstrated by glomerular PAS staining and increased glomerular and tubular collagen I and 
III deposition, as is predicted in diabetes (56). Kidney weight is partially reduced in the D-
podVEGFC mice. This may indicate a reduction in early fibrosis as a result of reduced albumin 
filtration and therefore reduced tubular toxicity (57). 
We suggest the differing effects between VEGFC and VEGFA may be due to differential 
activation of VEGFR2. We have previously shown that VEGFC does not induce VEGFR3 
phosphorylation in ciGEnC, yet  promotes delayed VEGFR2 phosphorylation at 30min 
compared to rapid phosphorylation by VEGFA at 2min (32). However, we show that VEGFC 
causes rapid loss of cell surface VEGFR3 expression, suggesting internalisation of VEGFR3 by 
VEGFC. In otherwise healthy glomeruli, chronic glomerular VEGFC expression induced 
VEGFR2 and VEGFR3 heterodimerisation and reduced glomerular VEGFA mRNA expression 
without inducing glomerular fibrosis or a loss of glomerular function or changes in glomerular 
ultrastructure. This is important since reduced glomerular VEGFA expression can lead to renal 
thrombotic microangiopathy and proteinuria (26; 44), yet increased glomerular VEGFA 
expression can lead to collapsing glomerulopathies and proteinuria (44). That VEGFC has no 
detrimental effect on glomerular function is fundamentally important to future studies aiming to 
manipulate the VEGFC pathway in order to protect glomeruli. It is known that VEGFC induces 
VEGFR2/VEGFR3 heterodimerisation in lymphatic endothelial cells (45). Here, we demonstrate 
that chronic exposure to VEGFC induces heterodimerisation in glomeruli. Also, glomerular 
VEGFA expression is repressed, similarly to when Ang-1 is overexpressed (58), potentially 
altering receptor availability to VEGFC and thus facilitating heterodimerisation. Interestingly, 
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heterodimerisation of VEGFR3 with VEGFR2 leads to reduced phosphorylation of some 
tyrosine sites in lymphatic endothelial cells (45). These results suggest that VEGFR3 is involved 
in VEGFC signalling, confirm functional activity of overexpressed VEGFC and demonstrate for 
the first time in vivo that mouse VEGFC induces VEGFR2/VEGFR3 heterodimerisation. Thus, 
the change in glomerular VEGFR complex formation may explain the different temporal effects 
on VEGFR2 phosphorylation by VEGFA and VEGFC. Interestingly, VEGFC also protected 
from a diabetes-induced increase in VEGF receptor expression in glomeruli. These data support 
previous observed increases in VEGFR2 expression in DN (59; 60), although changes in 
glomerular VEGFR3 expression are not well documented. VEGFR2 and VEGFR3 expression 
were both reduced in D-podVEGFC mice, therefore the potential for heterodimerisation 
remained the same. However, the potential for receptor phosphorylation may be reduced, thereby 
reducing downstream signalling. Glomerular VEGFA is known to be upregulated in early DN 
(18) and most glomerular VEGF-receptor complexes are localized to GEnC (18). This indicates 
that VEGFA predominantly regulates the endothelial phenotype during diabetic glomerulopathy, 
although endothelial cells are thought to “signal back” to the podocytes, inducing their injury 
(44). Hohenstein et al demonstrated that mildly injured glomeruli in early DN (relating to 
glomeruli in our study) had increased VEGFA-bound receptor complexes, whereas more 
severely injured glomeruli had decreased VEGFA-bound receptor complexes (18). Perhaps the 
key for VEGFC-mediated protection is to competitively reduce VEGFA receptor signalling, 
particularly in early DN. 
VEGFC induces lymphatic hyperplasia and is associated with lymphangiomas and 
lymphangiosarcomas (61). Subcutaneous VEGFC overexpression also increases obesity and 
insulin resistance (62) and VEGFC is implicated in inflammation in late DN (63). Therefore, it is 
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unlikely that VEGFC can be given therapeutically in its native form, although, of note, it was 
used successfully in mice to treat polycystic kidney disease (64), to treat renal interstitial fibrosis 
for 14 days (65) and we gave VEGFC daily i.p for a total of 7 days with no gross morphological 
effects. Lymphangiogenesis is increased in the tubular-interstitium in DN (63) and this is 
considered a protective mechanism to aid drainage (66), but may also promote inflammation 
(67). If this mechanism is saturated, it can lead to oedema in the kidney, as suggested by (66). 
Importantly, in a model of unilateral ureteral obstruction, VEGFC treatment by osmotic mini-
pump attenuated infiltration of inflammatory cells (65). We have not yet investigated whether 
lymphangiogenesis is promoted in podVEGFC mice, but this is an important consideration in 
diabetes and is another potential reason for reduced hypertrophy in podVEGFC diabetic mice. 
Whether VEGFC can act as a microvascular protectant in other vascular beds in diabetes remains 
to be seen. In order to harness the effects of VEGFC therapeutically it may be more appropriate 
to target the VEGFC signalling pathway. One such approach would be to target the 
VEGFR2/VEGFR3 complex as previously for VEGFR1/VEGFR2 complexes (68). Another 
would be to target signalling pathways that promote eGLX synthesis. If VEGFC can protect 
from diabetes-induced glycocalyx damage, then this is another exciting avenue of treatment. We 
have shown that VEGFC can protect against increased Ps’alb caused by systemic eGLX damage, 
both in chronic and acute models. We have also previously shown in vitro that VEGFA induced 
eGLX shedding in GEnC whilst VEGFC induced eGLX synthesis (33). As highlighted above, 
the D-podVEGFC mice did not suffer from significant fenestration density loss. The restoration 
of filtration control for albumin is potentially due to altered e-GLX coverage of the fenestrations. 
Since eGLX dysfunction is considered an early insult in DN (69), and the type I diabetes models 
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used show an early phenotype, perhaps VEGFC mediates its protection though eGLX restoration 
in early DN. This will be a focus of future work.  
Importantly, we have demonstrated a novel role for VEGFC in the development of early 
DN. 
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Figure legends 
Figure 1. VEGFC prevents the increase in glomerular albumin permeability caused by VEGFA 
and type II diabetes. Glomeruli were sieved from healthy mice (FVB/mixed background (A) and 
db/+ lean control (B)) and stimulated ex vivo with vehicle, 1nM VEGFA, 10nM VEGFC or both 
for 1hr at 37ºC and Ps’alb measured (one-way ANOVA with Bonferroni post hoc tests 
indicated). Glomeruli were sieved from db/+ and db/db mice at 12-14wk and incubated ex vivo 
with (+) or without (-) VEGFC, then Ps’alb measured (C, one-way ANOVA, Bonferroni post 
hoc tests indicated). Number of animals indicated outside brackets and number of glomeruli 
indicated inside brackets. UACR (D) and blood glucose (E) are shown for db/+ and db/db mice 
at 12-14wk. Fold change in VEGFA mRNA expression in sieved glomeruli from db/+ and db/db 
mice is shown (F, n= 6 and 5 respectively).*=p<0.05, **=p<0.01, ***=p<0.001. 
Figure 2. Characterization of podVEGFC mouse. A. A 2.5-kb fragment of the NPHS2promoter-
enhancer region directs the expression of reverse tetracycline-controlled transcriptional activator 
rtTA in podocytes. In the presence of doxycycline, a transcriptional activator fusion protein 
binds to the tetracycline-response operon promoter element (TetO) and initiates mouse VEGFC 
transcription (29). B. Glomeruli were isolated from podVEGFC (podVC) or LMC (littermate 
control) mice after receiving doxycycline for 3 wk. mRNA was extracted and QPCR performed 
for VEGFC, normalised to GAPDH and to LMC animals (2-^^CT) (*=p<0.05, unpaired t-test, 
n=3). C. Kidneys from LMC and podVEGFC mice on doxycycline for 8 weeks were removed, 
snap frozen and co-immunofluorescence was performed with anti-VEGFC (green), anti-nephrin 
(red) antibody and DAPI (blue). Representative confocal images are shown. Images are shown at 
10x (I, scale bar = 25µm) and x40 (ii, Scale bar= 70µm). D. Semi-quantification was performed 
on glomeruli (VEGFC/Dapi) and presented as fold change (p<0.05, unpaired t-test, n=9 and 5 
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respectively). Kidneys from LMC and podVEGFC mice given doxycycline for 8 wk were 
weighed and expressed as a ratio to total body weight (E). Periodic acid Schiff’s (PAS) staining 
and ultrastructural changes were imaged (Fi and Fii). PAS staining was quantified (G, n=5&8) 
as were parameters of glomerular ultrastructure, including glomerular basement membrane 
(GBM) width, podocyte foot (FP) process width, slit diaphragm (SD) length (H, n=4&8) and 
fenestration density per µm length GBM (I, n=4&8). Weekly urine albumin creatinine ratios 
(uACR) are expressed (J, n=6&5). N.s. = non-significant. 
Figure 3. VEGFC overexpression affects VEGFA and VEGF receptors. Glomeruli were 
enriched from podVEGFC and littermate control (LMC) mice. Quantitative PCR was performed 
and normalised to GAPDH and LMC mice (2-^^CT). Relative VEGFR2 (A), VEGFR3 (B) and 
VEGFA (C) mRNA expression is shown (n=3. *=p<0.05, unpaired t-test). Human GEnC were 
stimulated with VEGFC or VEGFA for 2min then fixed, non-permeabilised or permeabilised and 
stained for VEGFR3 or IgG control (scale bar 50µm). Representative images are shown (Di). 
Fold change in mean fluorescent intensity of VEGFR3 per cell is shown for non-permeabilised 
(Dii) and permeabilized (Diii) GEnC (n=5-6, p<0.001 one-way ANOVA). Isolated glomeruli (E) 
and homogenised lung (F) from wild type mice were treated ex vivo with vehicle, VEGFC 
(30min) and VEGFA (2min, glomeruli fractions only). Samples were immunoprecipiated with 
anti-VEGFR3 then probed with anti-VEGFR3 or anti-VEGFR2. These are representative blots 
from 3 separate experiments. A proximity ligation assay was performed on fresh frozen kidney 
sections from LMC or podVEGFC mice using antibodies to VEGFR2 and VEGFR3 (G, scale 
bar 25µM). Punctate events were counted through Z stacks in glomeruli (outlined) and expressed 
per nuclei (H).*=p<0.05, unpaired t-test, n=6 and 3.  
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Figure 4. Early VEGFC expression reduces the development of DN. Mice were given 
doxycycline at the same time as STZ injections, at wk0 (A). Glycemia (B), body weight (C) 
urine output (D), kidney/body weight ratio (E, p<0.05, one-way ANOVA) were monitored 
weekly post injection in D-LMC (diabetic) and D-podVEGFC mice compared to sham-LMC 
mice (n=11, 3 &5). Log fold change to baseline in uACR is shown at 8wk post STZ injection (F, 
p<0.05, one-way ANOVA, n=11, 11 & 5 respectively). Mice were cardiac perfusion fixed. 
Representative electron micrographs are shown at high power to show details of capillary loops 
in sham-littermate control (LMC) (Gi), diabetic LMC (D-LMC) (Gii) and diabetic podVEGFC 
(D-podVEGFC) (Giii). Arrows highlight reduced endothelial fenestration density and 
arrowheads highlight flattened foot processes. Ultrastructural changes were quantified by 
measuring GBM width, podocyte foot process width (p<0.05, one-way ANOVA) and slit 
diaphragm (SD) length (n= 7, 4 &5 respectively, p<0.001, one-way ANOVA, H). Endothelial 
fenestration density per µm of GBM was also quantified (n= 7, 4&5, p<0.05, one-way ANOVA, 
I). Bonferroni post hoc tests indicated; *=p<0.05, **=p<0.01, ***=p<0.001, n=5, 3&4. D-
podVC=D-podVEGFC. 
Figure 5. VEGFC intervention reduces the development of DN.. Mice were given STZ 
injections at wk 0, then given doxycycline after the establishment of hyperglycemia at wk 4 (A). 
Glycemia (B, n=4, 20 & 9), urine output (C, n=4, 16 & 11) and body weight (D, n=4, 20 & 9) 
were measured weekly in sham-LMC, diabetic littermate control (D-LMC) and diabetic 
podVEGFC (D-podVC) mice. Plasma uric acid (E, p<0.05, one-way ANOVA), kidney:body 
weight ratio (F, p<0.05 one way ANOVA, n=4, 10&9) and urine albumin creatinine ratios 
(uACR), presented as log fold change to baseline (G, p<0.05, one way ANOVA, n=5, 18 &15) 
were also measured at 8 wk post injection. Representative Periodic acid Schiff’s (PAS) staining 
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was performed on paraffin embedded kidney sections from sham-LMC, D-LMC and D-
podVEGFC mice (H). Representative picrosirius red immunohistochemistry images are 
demonstrated under brightfield (I) and polarized (J) lens (n=3). PAS staining intensity is 
quantified using Quantity One (K, p<0.001, one-way ANOVA, n=3). Post hoc tests indicated, 
*=p<0.05, **=p<0.01, ***=p<0.001. 
Figure 6. VEGFC intervention ameliorates early ultrastructural changes in DN. Mice given 
doxycycline at 4wk post STZ were cardiac perfusion fixed. Representative electron micrographs 
are shown at high power to show details of capillary loops in sham-littermate control (LMC) 
(Ai), Diabetic–LMC (D-LMC) (Aii) and D-podVEGFC (D-podVC) (Aiii). Arrows highlight 
reduced endothelial fenestration density and arrowheads highlight flattened foot processes. 
Ultrastructural changes were quantified by measuring GBM width, podocyte foot process width 
(p<0.05, one-way ANOVA) and slit diaphragm (SD) length (n= 4, 6 &3 respectively, p<0.001, 
one-way ANOVA, B). Endothelial fenestration density per µm of GBM were also quantified 
(p<0.05, one-way ANOVA, C). n=4, 6 & 3. Bonferroni post hoc tests indicated; *=p<0.05, 
**=p<0.01, ***=p<0.001. 
Figure 7. Glomerular VEGFC prevents the diabetes associated changes in VEGFR expression. 
Glomeruli enriched fractions from sham littermate control (LMC), diabetic podVEGFC (D-
podVC) and littermate control (D-LMC) mice given doxycycline from 4wk post injection. 
mRNA was extracted and quantified using qPCR normalised first to GAPDH then LMC (2-
^^CT). Glomerular enriched fraction VEGFC expression is demonstrated by QPCR in D-
podVEGFC compared to D-LMC mice (i.e. overexpressed) (A, p<0.05, unpaired t-test, n=4) and 
in D-LMC compared to sham mice (i.e. endogenous) (B, n=4). Glomerular enriched fraction 
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VEGFA mRNA expression is demonstrated by QPCR in sham-LMC, D-LMC and D-
podVEGFC mice (C, p<0.05, one-way ANOVA, n=3). Glomerular VEGFR2 (D, p<0.01, one-
way ANOVA, n=3, 3 & 4) and VEGFR3 (E, p<0.05, one-way ANOVA, n=3, 3 & 4) expression 
in sham-LMC, D-LMC and D-podVEGFC mice are shown. Expression changes at the protein 
level for VEGFR3 and VEGFR2 were confirmed by Western blotting in isolated glomeruli from 
the same groups of mice. VEGFR2 overexpressing GEnC (GEnC-R2) and mouse spleen were 
used as positive controls for VEGFR2 and VEGFR3 respectively (F, n=3). Normalised density to 
actin, then sham for VEGFR2 (G, n=3, p<0.01) and VEGFR3 (H, n= 4, 6&3 respectively) is 
shown. Bonferroni post hoc tests indicated, *=p<0.05, **=p<0.01, ***=p<0.001. 
Figure 8.  VEGFC protects against raised Ps’alb caused by systemic eGLX dysfunction. 
FVB/mixed background mice were administered hyaluronidase and chondroitinase either acutely 
(30min i.v. A) or chronically (osmotic minipump, 2wk B-F). Glomeruli isolated from mice with 
acute eGLX dysfunction (enzymes +) were incubated ex vivo with (+) VEGFC, then Ps’alb 
measured and compared to historical data without (-) VEGFC (grey(40) ) (A, one-way ANOVA 
with Bonferroni post hoc tests indicated). Mice exposed to enzymes chronically over a period of 
2wk were given VEGFC i.p in the last week. Ps’alb measurements were taken in isolated 
glomeruli (B, one-way ANOVA, Bonferroni post hoc tests indicated). Representative EM images 
of the glomerular filtration barrier for each condition (n=4, 3, 4 respectively) are shown with e-
GLX highlighted (white brackets, C, scale bar 100nm). Glomerular ultrastructural parameters 
from these mice were quantified; eGLX depth, podocyte GLX depth (D, one-way ANOVA with 
Bonferroni post hoc tests indicated, n.s. = non-significant), glomerular basement membrane 
(GBM) thickness (one way ANOVA, Bonferroni post-hoc tests indicated), podocyte foot process 
(FP) width, slit diaphragm (SD) length (E, p<0.05, one way ANOVA, no post hoc test 
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significance) and endothelial fenestration density (F). *=p<0.05, **=p<0.01 (dashed lines 
indicate comparison of previously published data) ***=p<0.001. 
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